-
Document de presse | 2021.12.23
COVID-19 – Omicron: resistant to most monoclonal antibodies but neutralized by a booster dose
The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries. It is expected to become the dominant variant within a few weeks or months. Initial epidemiological studies show that the Omicron variant is more transmissible than the currently dominant virus (the Delta variant). It is capable of spreading to individuals who have received...
-
Fiche maladie | 2018.12.05
Cholera
Cholera is an epidemic acute diarrheal disease that only affects humans and is caused by serogroup O1 (and in rare cases O139) of the Vibrio cholerae bacterium. Although this infection is sometimes caused by direct contact with infected individuals (e.g. through unwashed hands, last offices, etc.), it is more commonly attributable to the ingestion of water or food contaminated with the feces of...
-
Fiche maladie | 2020.09.23
Meningococcal meningitis
Meningitis is an infection of the spinal cord and the brain membranes – or meninges –, caused by several types of virus, bacteria and fungi. Meningococci (another name for Neisseria meningitidis bacteria) are the main cause of acute meningitis. Despite treatment, meningococcal infections have a high mortality rate (10%) and considerable epidemic potential.
-
Document de presse | 2015.02.02
Moderna and Institut Pasteur Sign Strategic Research Collaboration
Research partnership will advance the development of mRNA vaccines and passive immunity therapies for infectious diseases. Press releaseCAMBRIDGE, Mass. (USA) and Paris (France), Feb. 3rd, 2015 Moderna Therapeutics, a pioneer in the development of messenger RNA (mRNA) Therapeutics™ and the Institut Pasteur, a recognized public benefit organization with three core missions -...
-
Document de presse | 2017.03.31
A new approach for improving BCG
Scientists at the Institut Pasteur and their partners in the international TBVAC2020 consortium have just developed a tuberculosis vaccine candidate derived from conventional BCG. This vaccine candidate has higher efficacy, due to a heterologous system of protein secretion that increases the quality and magnitude of the immune responses to virulent strains of Mycobacterium tuberculosis – the...
-
News | 2017.06.22
A strategy for attenuating a virus by modifying its evolutionary potential
RNA viruses, like influenza viruses, have broad genetic variability, which gives them a high adaptive potential. As part of the fight against RNA viruses, scientists at the Institut Pasteur – evolutionary virologists – decided to alter their future. Along with colleagues from Lund University (Sweden), they succeeded in altering the genomes of an enterovirus and an influenza virus, thereby...
-
Document de presse | 2023.11.14
Significant "post-COVID" resurgence in invasive meningococcal disease
A team of scientists from the Institut Pasteur has used the database of the National Reference Center for Meningococci to trace the evolution of invasive meningococcal disease cases in France between 2015 and 2022, revealing an unprecedented resurgence in the disease after the easing of control measures imposed during the COVID-19 epidemic. Recently reported cases have mainly been caused by...
-
Article | 2024.04.30
Charles Chamberland, the inventor of sterilization tools
Physicist and biologist Charles Chamberland was one of Louis Pasteur’s earliest associates. Associated with much of his tutor’s work, he was also a great inventor, designing an autoclave and a water filter, which are both named after him.
-
News | 2025.04.30
5 reasons to follow the MOOC "Viruses and Human Cancers"
Did you know that certain viruses can cause cancer? Which viruses and which cancers are involved? How do we explain the link between viruses and cancer? Follow the MOOC “Viruses and Human Cancers” to find out more.
-
News | 2013.10.09
Fine-tuning the approach to malaria and toxoplasmosis research
A study carried out by teams from the Institut Pasteur, the Institut Cochin (Inserm, CNRS, Paris Descartes University), and the Wellcome Trust Centre for Molecular Parasitology at the University of Glasgow, may very well redefine current approaches to malaria and toxoplasmosis research in terms of treatment development. Their research which focuses on the role played by the protein AMA1 (present...